

# QUICK FACTS CHRONIC WOUNDS

## GLOBAL PROBLEM EXACERBATED BY BIOFILM

up to **2%**  
of the population  
in developed  
countries suffer  
from chronic  
wounds<sup>1</sup>

**6.7 million  
Americans**  
**20 million  
worldwide**  
treated for chronic  
wounds per year<sup>2-3</sup>

U.S. cost:  
**\$20 - \$50  
billion**  
per year<sup>2</sup>

Developed  
countries cost:  
**3 - 5%**  
of total healthcare  
expenditures<sup>4</sup>

Type of Chronic Wound	Annual Treatment Cost (US)	Patient Cost per Wound
<b>Pressure Ulcers</b>	>\$11 billion <sup>5</sup>	\$20,900 - \$151,700 <sup>5</sup>
<b>Diabetic Foot Ulcers</b>	\$9 - \$13 billion <sup>5</sup>	\$50,000 <sup>6</sup>
<b>Venous Ulcers</b>	\$2.5 billion <sup>5</sup>	>\$34,000 <sup>5</sup>

### Recurrence Rates

**Pressure  
Ulcers**

**31 - 79%**<sup>7</sup>

**Diabetic  
Foot Ulcers**


**8 - 59%**<sup>8</sup>

**Venous Ulcers**

**70%**<sup>3</sup>

Biofilm infection may directly hinder wound closure or cause defective wound closure, leading to wound recurrence.<sup>5</sup>

### Biofilm complicates chronic wounds



~78% of wounds are infected with bacterial biofilm<sup>9</sup>

- Key cause of delayed wound healing
- Shields the infection from the patient's immune response and antibiotics<sup>5</sup>


#### REFERENCES

1. Nussbaum S, et al. (2018). An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. *Value Health*, 27-32. 2. MedMarket Diligence, LLC. (2018). Billions in Global Wound Product Sales, Yet Chronic Wounds Remain a Chronic Problem, Base on New Research from MedMarket Diligence. PR.com, 1-2. 3. Wound Reach Foundation. (2013-2019). The Challenge. When Was the Last Time You Said "Ouch!?" [www.woundreach.org/why-wounds/the-challenge](http://www.woundreach.org/why-wounds/the-challenge). 4. Jarbrink K, et al. (2017). The Humanistic and Economic Burden of Chronic Wounds: A Protocol for a Systematic Review. *Syst Rev*, 1-7. 5. Sen C. (2019). Human Wounds and Its Burden: An Updated Compendium of Estimates. *Adv Wound Care*, 39-48. 6. Han G. (2017). Chronic Wound Healing: A Review of Current Management and Treatments. *Adv Ther*, 599-610. 7. Bruin Biometrics. (2013). Pressure Ulcer Formation: Patients Populations at Highest Risk. White Paper, 1-7. 8. Lavery L, et al. (2016). WHS Guidelines Update: Diabetic Foot Ulcer Treatment Guidelines. *Wound Repair Regen*, 112-126. 9. Malone M, et al. (2017). The Prevalence of Biofilms in Chronic Wounds: A Systematic Review and Meta-Analysis of Published Data. Montana State University, 1-5.

### Treat Chronic Wounds with Procellera

Published studies demonstrate Procellera's ability to:

- Kill a broad-spectrum of microbes, including multidrug-resistant and biofilm-forming bacteria
- Disrupt established biofilm infection
- Prevent biofilm from forming



**Procellera™**  
ANTIMICROBIAL WOUND DRESSING  
POWERED BY V.DOX™ TECHNOLOGY

[vomaris.com](http://vomaris.com)

Please review the Instructions for Use for a complete list of indications, contraindications, warnings, and precautions.

© 2022 Vomaris. All rights reserved. Vomaris logo, Vomaris, Procellera, and V.Dox are trademarks of Vomaris Innovations, Inc.

K-93 Rev. C

Vomaris Wound Care, Inc.

1911 East Fifth Street | Tempe, AZ 85288 USA

+1 (480) 921-4948 | (866) 496-8743

